From a BioElectronics Corp (BIEL) investor’s per
Post# of 8680
(Total Views: 252)
Posted On: 09/22/2025 2:31:03 PM
From a BioElectronics Corp (BIEL) investor’s perspective, this observational study published in Medicinski Glasnik offers a compelling endorsement of the ActiPatch device’s clinical utility and market potential.
https://medicinskiglasnik.ba/article/2030
Investor-Focused Summary:
ActiPatch in Post-Surgical Pain Management
Study Title: Effectiveness of ActiPatch in the management and prevention of pillar pain following open carpal tunnel release surgery in weight-bearing hand of elderly patients
Study Design
Population: 10 elderly patients with pillar pain post–carpal tunnel release surgery.
Intervention: ActiPatch used for 7 days post-op; later used preemptively on opposite hand before second surgery.
Metrics: Pain (VAS), functionality (QuickDASH, MHQ), and patient satisfaction.
Key Findings
Pain Reduction: All patients experienced significant pain relief after ActiPatch use.
Functionality Gains: Improved hand function scores across the board.
Preventive Success: No pillar pain occurred when ActiPatch was used preemptively before second-hand surgery.
Strategic Implications for BIEL
Clinical Validation: Reinforces ActiPatch’s effectiveness in a targeted, high-need population—elderly patients undergoing hand surgery.
Preventive Use Case: Opens the door for ActiPatch to be positioned not just as a treatment, but as a preventive tool, expanding its therapeutic scope.
International Recognition: Published in a European medical journal, this study may support BIEL’s global expansion strategy, especially in EU markets.
Low-Cost, Non-Pharma Alternative: Aligns with growing demand for drug-free pain management solutions, especially in aging populations.
This study strengthens the narrative that ActiPatch is more than a niche device—it’s a scalable, clinically backed solution for chronic and post-operative pain. For investors, it’s another brick in the wall of credibility that BIEL needs to attract partnerships, regulatory traction, and broader adoption.
https://medicinskiglasnik.ba/article/2030
Investor-Focused Summary:
ActiPatch in Post-Surgical Pain Management
Study Title: Effectiveness of ActiPatch in the management and prevention of pillar pain following open carpal tunnel release surgery in weight-bearing hand of elderly patients
Study Design
Population: 10 elderly patients with pillar pain post–carpal tunnel release surgery.
Intervention: ActiPatch used for 7 days post-op; later used preemptively on opposite hand before second surgery.
Metrics: Pain (VAS), functionality (QuickDASH, MHQ), and patient satisfaction.
Key Findings
Pain Reduction: All patients experienced significant pain relief after ActiPatch use.
Functionality Gains: Improved hand function scores across the board.
Preventive Success: No pillar pain occurred when ActiPatch was used preemptively before second-hand surgery.
Strategic Implications for BIEL
Clinical Validation: Reinforces ActiPatch’s effectiveness in a targeted, high-need population—elderly patients undergoing hand surgery.
Preventive Use Case: Opens the door for ActiPatch to be positioned not just as a treatment, but as a preventive tool, expanding its therapeutic scope.
International Recognition: Published in a European medical journal, this study may support BIEL’s global expansion strategy, especially in EU markets.
Low-Cost, Non-Pharma Alternative: Aligns with growing demand for drug-free pain management solutions, especially in aging populations.
This study strengthens the narrative that ActiPatch is more than a niche device—it’s a scalable, clinically backed solution for chronic and post-operative pain. For investors, it’s another brick in the wall of credibility that BIEL needs to attract partnerships, regulatory traction, and broader adoption.
(1)
(0)